News – Seaport Therapeutics

Press Release - 2026-03-03

Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

Press Release - 2026-02-20

Seaport Therapeutics Presents New Meta-Analysis Examining the Impact of Clinical Trial Design Factors on Placebo Response in Generalized Anxiety Disorder Trials

Press Release - 2026-02-18

Seaport Therapeutics to Participate in Upcoming Investor Conferences in February and March

Press Release - 2026-01-05

Seaport Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Press Release - 2025-12-08

Seaport Therapeutics Presents Data Further Validating GlyphTM Platform’s Ability to Enhance Oral Bioavailability and Expand Therapeutic Reach

Press Release - 2025-12-04

Seaport Therapeutics to Present at 2025 RBC Capital Markets Healthcare Private Company Conference

Press Release - 2025-11-04

Seaport Therapeutics to Present at Stifel 2025 Healthcare Conference

Press Release - 2025-09-18

Seaport Therapeutics to Participate in Upcoming Investor Conferences

Press Release - 2025-09-11

Seaport Therapeutics Advances Second Therapeutic Candidate into Clinical Development with Dosing of First Participant in Phase 1 Study of GlyphAgo (SPT-320) in Healthy Volunteers

Press Release - 2025-07-17

Seaport Therapeutics Announces First Patient Dosed in Phase 2b BUOY-1 Study of GlyphAllo (SPT-300) in Major Depressive Disorder (MDD), With or Without Anxious Distress